Cannabis use, first-episode psychosis, and schizotypy: A summary and synthesis of recent literature

Current Psychiatry Reviews

Volumn 3, Issue 3, 2007, Pages 161-171

  Compton, Michael T ^a,b   Goulding, Sandra M ^b   Walker, Elaine F ^c  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

^c EMORY UNIVERSITY   (United States)

Author keywords

Cannabis; First episode psychosis; Marijuana; Psychosis; Schizophrenia; Schizotypy

Indexed keywords

CANNABIS;

CANNABIS ADDICTION; CAUSAL ATTRIBUTION; DISEASE ASSOCIATION; DISEASE COURSE; GENETIC PREDISPOSITION; HUMAN; MEDICAL RESEARCH; NEUROPATHOLOGY; PREVALENCE; PRIORITY JOURNAL; PSYCHOLOGICAL RATING SCALE; PSYCHOSIS; REVIEW; RISK FACTOR; SCHIZOPHRENIA; SCHIZOTYPAL PERSONALITY DISORDER; SCORING SYSTEM;

EID: 34548303250     PISSN: 15734005     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340007781369658     Document Type: Review

References (166)

1. Keshavan MS, Gilbert AR, Diwadkar VA. Neurodevelopmental theories. In: Lieberman JA, Stroup TS, Perkins DO. Textbook of Schizophrenia. Washington, DC: American Psychiatric Publishing, 2006, 69-83.
2. Walker EF, Diforio D. Schizophrenia: A neural diathesis-stress model. Psychol Rev 1997; 104: 667-685.
3. Tully EM, McGlashan TH. The prodrome. In: Lieberman JA, Stroup TS, Perkins DO. Textbook of Schizophrenia. Washington, DC: American Psychiatric Publishing, 2006, 341-352.
4. Walker E, Lewine RJ. Prediction of adult-onset schizophrenia from childhood home movies of the patients. Am J Psychiatry 1990; 147: 1052-1056.
5. Reichenberg A, Weiser M, Rabinowitz J, et al. A population-based cohort study of premorbid intellectual, language, and behavioral functioning in patients with schizophrenia, schizoaffective disorder, and nonpsychotic bipolar disorder. Am J Psychiatry 2002; 159: 2027-2035.
6. Strous RD, Alvir JMJ, Robinson D, et al. Premorbid functioning in schizophrenia: Relation to baseline symptoms, treatment response, and medication side effects. Schizophr Bull 2004; 30: 265-278.
7. Jarskog LF, Gilmore JH, Lieberman JA. Neurodegenerative models of schizophrenia. In: Keshavan M, Kennedy J, Murray R. Neurodevelopment and Schizophrenia. Cambridge: Cambridge University Press, 2004, 373-389.
8. McGlashan TH, Hoffman RE. Schizophrenia as a disorder of developmentally reduced synaptic connectivity. Arch Gen Psychiatry 2000; 57: 637-648.
9. Stephan KE, Baldeweg T, Friston KJ. Synaptic plasticity and dysconnection in schizophrenia. Biol Psychiatry 2006; 59: 929-939.
10. Boydell J, van Os J, Murray RM. Is there a role for social factors in a comprehensive developmental model for schizophrenia? In: Keshavan M, Kennedy J, Murray R. Neurodevelopment and Schizophrenia. Cambridge: Cambridge University Press, 2004, 224-247.
11. Cannon M, Dean K, Jones PB. Early enviromental risk factors for schizophrenia. In: Keshavan M, Kennedy J, Murray R. Neurodevelopment and Schizophrenia. Cambridge: Cambridge University Press, 2004, 191-209.
12. Caspi A, Moffitt TE, Cannon M, et al. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: Longitudinal evidence of a gene X environment interaction. Biol Psychiatry 2005; 57: 1117-1127.
13. Raine A, Reynolds C, Lencz T, et al. Cognitive-perceptual, interpersonal, and disorganized features of schizotypal personality. Schizophr Bull 1994; 20: 191-201.
14. Gruzelier JH. The factorial structure of schizotypy: part I. affinities with syndromes of schizophrenia. Schizophr Bull 1996; 22: 611-620.
15. Bergman AJ, Silverman JM, Harvey PD, Smith CJ, Siever LJ. Schizotypal symptoms in the relatives of schizophrenia patients: An empirical analysis of the factor structure. Schizophr Bull 2000; 26: 577-586.
16. Fanous A, Gardner C, Walsh D, Kendler KS. Relationship between positive and negative symptoms of schizophrenia and schizotypal symptoms in nonpsychotic relatives. Arch Gen Psychiatry 2001; 58: 669-673.
17. Siever LJ, Davis KL. The pathophysiology of schizophrenia disorders: Perspectives from the spectrum. Am J Psychiatry 2004; 161: 398-413.
18. Claridge GS. Single indicator of risk for schizophrenia: Probable fact or likely myth? Schizophr Bull 1994; 20: 151-168.
19. Bedwell JS, Donnelly RS. Schizotypal personality disorder or prodromal symptoms of schizophrenia? Schizophr Res 2005; 80: 263-269.
20. American Psychiatric Association (APA). Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association, 2000: 685-729.
21. Kendler KS, McGuire M, Gruenberg AM, Walsh D. Schizotypal symptoms and signs in the Roscommon Family Study. Their factor structure and familial relationship with psychotic and affective disorders. Arch Gen Psychiatry 1995; 52: 296-303.
22. Jacobs N, Myin-Germeys I, Derom C, Vlietinck R, van Os J. Deconstructing the familiality of the emotive component of psychotic experiences in the general population Acta Psychiatr Scand 2005; 112: 394-401.
23. MacDonald AW 3rd, Pogue-Geile MF, Debski TT, Manuck S. Genetic and environmental influences on schizotypy: a community-based twin study. Schizophr Bull 2001; 27: 47-58.
24. Linney YM, Murray RM, Peters ER, MacDonald AM, Rijsdijk F, Sham PC. A quantitative genetic analysis of schizotypal personality traits. Psychol Med 2003; 33: 803-816.
25. Kendler KS, Czajkowski N, Tambs K, et al. Dimensional representations of DSM-IV cluster A personality disorders in a population-based sample of Norwegian twins: a multivariate study. Psychol Med 2006; 36: 1583-1591.
26. Skosnik PD, Spatz-Glenn L, Park S. Cannabis use is associated with schizotypy and attentional disinhibition. Schizophr Res 2001; 48: 83-92.
27. Castle DJ, Solowij N. Acute and subacute psychomimetic effects of cannabis in humans. In: Castle DJ, Murray R. Marijuana and Madness. Cambridge: Cambridge University Press, 2004, 41-53.
28. Ashton CH. Adverse effects of cannabis and cannabinoids. Br J Anaesth 1999; 83: 637-649.
29. Ashton CH. Pharmacology and effects of cannabis: A brief review. Br J Psychiatry 2001; 178: 101-106.
30. Mechoulam R, Hanus L. The cannabinoid system: from the point of view of a chemist. In: Castle DJ, Murray R. Marijuana and Madness. Cambridge: Cambridge University Press, 2004, 1-8.
31. Musty RE, Reggio P, Consroe P. A review of recent advances in cannabinoid research and the 1994 International Symposium on Cannabis and the Cannabinoids. Life Sci 1995; 56: 1933-1940.
32. Adams IB, Martin BR. Cannabis: pharmacology and toxicology in animals and humans. Addiction 1996; 91: 1585-1614
33. Abood ME, Martin BR. Neurobiology of marijuana abuse. Trends Pharmacol Sci 1992; 13: 201-206.
34. American Psychiatric Association (APA). Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association, 2000.
35. Substance Abuse and Mental Health Services Administration (SAMSHA). Results from the 2004 National Survey on Drug Use and Health: National Findings. NSDUH Series H-25. DHHS Pub. No. 04-3964. Rockville, MD: SAMHSA, 2005a.
36. National Institute on Drug Abuse (NIDA). Marijuana Info Facts. Accessed on June 22, 2006. http://www.drugabuse.gov/PDF/Info-Facts/ Marijuana06.pdf.
37. Anthony JC, Petronis KR. Early-onset drug use and risk of later drug problems. Drug Alc Depend 1995; 40: 9-15.
38. Grant BF, Dawson DA. Age at onset of drug use and its association with DSM-IV drug abuse and dependence: results from the national longitudinal alcohol epidemiologic survey. J Subst Abuse 1998; 10: 163-173.
39. Lynseky MT, Heath AC, Bucholz KK, et al. Escalation of drug use in early-onset cannabis users vs co-twin controls. JAMA 2003; 289: 427-433.
40. Compton WT, Grant BF, Colliver JD, et al. Prevalence of Marijuana Use Disorders in the United States: 1991-1992 and 2001-2002. JAMA 2004a; 291: 2114-2121.
41. Robins LN, Regier DA. Psychiatric Disorders in America. New York: Free Press, 1991.
42. Kessler RC, McGonagh KA, Zaho S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Arch Gen Psychiatry 1994; 51: 8-19.
43. Stinson FS, Ruan WJ, Pickering R, Grant BF. Cannabis use disorders in the USA: prevalence, correlates and co-morbidity. Psychol Med 2006; 36: 1447-1460.
44. Substance Abuse and Mental Health Services Administration (SAMSHA). Treatment Episode Data Set (TEDS). Highlights - 2003. National Admissions to Substance Abuse Treatment Services, DASIS Series: S-27, DHHS Publication No. (SMA 05-4043), Rockville, MD, 2005b.
45. Hall WD. Cannabis use and the mental health of young people. Austr NZ J Psychiatry 2006; 40: 105-113.
46. Mathers DC, Ghodse AH. Cannabis and psychotic illness. Br J Psychiatry 1992; 161: 648-653.
47. Nunez LA, Gurpegui M. Cannabis-induced psychosis: a cross-sectional comparison with acute schizophrenia. Acta Psychiatr Scand 2002; 105: 173-178.
48. Arendt M, Rosenberg R, Foldager L, Perto G, Munk-Jørgensen P. Cannabis-induced psychosis and subsequent schizophrenia-spectrum disorders: follow-up study of 535 incident cases. Br J Psychiatry 2005; 187: 510-515.
49. McGuire PK, Jones P, Harvey I, Williams M, McGuffin P, Murray RM. Morbid risk of schizophrenia for relatives of patients with cannabis-associated psychosis. Schizophr Res 1995; 15: 277-281.
50. Silver H, Abboud E. Drug abuse in schizophrenia: Comparison of patients who began drug abuse before their first admission with those who began abusing drugs after their first admission. Schizophr Res 1994; 13: 57-63.
51. Rabinowitz J, Bromet EJ, Lavelle J, et al. Prevalence and severity of substance use disorder and onset of psychosis in first-admission psychotic patients. Psychol Med 1998; 28: 1411-1419.
52. Sevy S, Robinson DG, Solloway S, et al. Correlates of substance abuse in patients with first-episode schizophrenia and schizoaffective disorder. Acta Psychiatr Scand 2001; 104: 367-374.
53. Bühler B, Hambrecht M, Löffler W, an der Heiden W, Häfner H. Precipitation and determination of the onset and course of schizophrenia by substance abuse - a retrospective and prospective study of 232 population-based first illness episodes. Schizophr Res 2002; 54: 243-251.
54. Linszen D, Peters B, de Haan L. Cannabis abuse and the course of schizophrenia. In: Castle DJ, Murray R. Marijuana and Madness. Cambridge: Cambridge University Press, 2004, 119-126.
55. Mauri MC, Volonteri LS, De Gaspari IF, et al. Substance abuse in first-episode schizophrenic patients: A retrospective study. Clin Pract Epidemiol Ment Health 2006; 2: 1-8.
56. Allebeck P, Adamsson C, Engstrom A, et al. Cannabis and schizophrenia: A longitudinal study of cases treated in Stockholm county. Acta Psychiatr Scand 1993; 88: 21-24.
57. Linszen DH, Dingemans PM, Lenior ME. Cannabis abuse and the course of recent onset schizophrenic disorders. Arch Gen Psychiatry 1994; 51: 273-279.
58. Arsenault L, Cannon M, Witton J, Murray R. Cannabis as a potential causal factor in schizophrenia. In: Castle DJ, Murray R. Marijuana and Madness. Cambridge: Cambridge University Press, 2004, 101-118.
59. Smit F, Boiler L, Cuijpers P. Cannabis use and the risk of later schizophrenia: A review. Addiction 2004; 99: 425-430.
60. Di Forti M, Murray RM. Cannabis consumption and risk of developing schizophrenia: Myth or reality. Epidemiol Psichiatri Sociale 2005; 14: 184-187.
61. Henquet C, Murray R, Linszen D, van Os J. The environment and schizophrenia: The role of cannabis use. Schizophr Bull 2005; 31: 608-612.
62. Weiser M, Noy S. Interpreting the association between cannabis use and increased risk for schizophrenia. Dialogues Clin Neurosci 2005; 7: 81-85.
63. Andréasson S, Allebeck P, Engström A, et al. Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. Lancet 1987, 2: 1483-1486.
64. Andréasson S, Allebeck P, Rydberg U. Schizophrenia in users and nonusers of cannabis. A longitudinal study in Stockholm County. Acta Psychiatr Scan 1989; 79: 505-510.
65. Chen CK, Murray RM. How does drug abuse interact with familial and developmental factors in the etiology of schizophrenia? In: Keshavan M, Kennedy J, Murray R. Neurodevelopment and Schizophrenia. Cambridge: Cambridge University Press, 2004, 248-269.
66. Zammit S, Allebeck P, Andréasson S, Lundberg I, Lewis G. Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: Historical cohort study. BMJ 2002; 325: 1199-1203.
67. Arseneault L, Cannorr M, Poulton R, et al. Cannabis use in adolescence and risk for adult psychosis: Longitudinal prospective study. BMJ 2002; 325: 1212-1213.
68. Weiser M, Reichenberg A, Rabinowitz J, et al. Self-reported drug abuse in male adolescents with behavioral disturbances, and follow-up for future schizophrenia. Biol Psychiatry 2003; 54: 655-660.
69. Fergusson DM, Poulton R, Smith PF, Boden JM. Cannabis and psychosis. BMJ 2006; 332: 172-176.
70. Rey JM, Martin A, Krabman P. Is the party over? Cannabis and juvenile psychiatric disorder The past 10 years. J Am Acad Child Adolesc Psychiatry 2004; 43: 1194-1205.
71. Ferdinand RF, Van der Ende J, Bongers I, et al. Cannabis - psychosis pathway independent of other types of psychopathology. Schizophr Res 2005; 79: 289-295.
72. Ferdinand RF, Sondeijker F, van der Ende J, Selten JP, Huizink A, Verhulst FC. Cannabis use predicts future psychotic symptoms, and vice versa. Addiction 2005; 100: 612-618.
73. Harrison PJ, Weinberger DR. Schizophrenia genes, gene expression, and neuropathology: On the matter of their convergence. Mol Psychiatry 2005; 10: 40-68.
74. 158Met moderation of cannabis induced psychosis: An experience sampling study (ESM) (abstract). Schizopbr Res 2006; 86: S25.
75. van Os J, Bak M, Bijl RV, et al. Cannabis use and psychosis: A longitudinal population-based study. Am J Epidemiol 2002; 156: 319-327.
76. Verdoux H, Gindre C, Sorbara F, et al. Effects of cannabis and psychosis vulnerability in daily life: An experience sampling test study. Psychol Med 2003; 33: 23-32.
77. Arseneault L, Cannon M, Witton J, et al. Causal association between cannabis and psychosis: Examination of the evidence. Br J Psychiatry 2004; 184: 110-117.
78. Semple DM, McIntosh AM, Lawrie SM. Cannabis as a risk factor for psychosis: Systematic review. J Psychopharmacol. 2005; 19: 187-194.
79. Moffitt TE, Caspi A, Rutter M. Strategy for investigating interactions between measured genes and measured environments. Arch Gen Psychiatry 2005; 62: 473-481
80. Hall W, Degenhardt L, Teesson M. Cannabis use and psychotic disorders: An update. Drug Alc Rev 2004; 23: 433-443.
81. Henquet C, Krabbendam L, Spauwen J, et al. Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. BMJ 2004; 330:11-16.
82. Verdoux H. Cannabis and psychosis proneness. In: Castle DJ, Murray R. Marijuana and Madness. Cambridge: Cambridge University Press, 2004, 75-88.
83. Ujike H, Morita Y. New perspectives in the studies on endocannabinoid and cannabis: Cannabinoid receptors and schizophrenia. J Pharmacol Sri 2004; 96: 376-381.
84. Devane WA, Dysarz FA, Johnson MR, et al. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 1988; 34: 605-613.
85. Iversen L. Cannabis and the brain. Brain 2003; 126: 1252-1270.
86. Iversen L. How cannabis works in the brain. In: Castle DJ, Murray R. Marijuana and Madness. Cambridge: Cambridge University Press, 2004, 19-40.
87. Sundram, S, Dean B, Copolov D. The endogenous cannabinoid system in schizophrenia. In: Castle DJ, Murray R. Marijuana and Madness. Cambridge: Cambridge University Press, 2004, 127-141.
88. D'Souza DC, Cho H-S, Perry EB, Krystal JH. Cannabinoid 'model' psychosis, dopamine-cannabinoid interactions and implications for schizophrenia. In: Castle DJ, Murray R. Marijuana and Madness. Cambridge: Cambridge University Press, 2004, 142-165.
89. Zammit S, Lewis G. Exploring the relationship between cannabis use and psychosis. Addiction 2004; 99: 1353-1355.
90. 3H]CP-55940 binding in the human central nervous system: Regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use. Neurosci 2001; 103; 9-15.
91. 3H]SR141716A binding to cannabinoid CB1 receptors is increased in the amenor cingulate cortex in schizophrenia. Progress Neuro-Psychopharmacol Biol Psychiatry 2004; 28: 355-360.
92. De Marchi N, De Petrocellis L, Orlando P, Daniele F, Fezza F, Di Marzo V. Endocannabinoid signaling in the blood of patients with schizophrenia. Lipids Health Dis 2003; 1-9.
93. Giuffrida A, Leweke FM, Gerth CW, et al. Cerebrospinal anandaminde levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacol 2004; 29: 2108-2114.
94. Leweke FM, Giuffrida A, Wurster U, Emrich HM, Piomelli D. Elevated endogenous cannabinoids in schizophrenia. Neuroreport 1999;10: 1665-1669.
95. Leroy S, Griffon N, Bourdel MC, Olié JP, Poirier MF, Krebs MO. Schizophrenia and the cannabinoid receptor type 1 (CB1): Association study using a single-base polymorphism in coding exon 1. Am J Med Genet (Neuropsychiatr Genet) 2001; 105: 749-752.
96. Ujike H, Takaki M, Nakata K, et al. CNR1, central cannabinoid receptor gene, associated with susceptibility to hebephrenic schizophrenia. Mol Psychiatry 2002; 7: 515-518.
97. Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse: Results from the Epidemiological Catchment Area (ECA) Study. JAMA 1990; 264: 2511-2518.
98. Drake RE, Osher FC, Wallach MA. Alcohol use and abuse in schizophrenia: A prospective community study. J Nerv Ment Dis 1989; 177: 408-414.
99. Mueser KT, Yarnold PR, Levinson DR, et al. Prevalence of substance abuse in schizophrenia: Demographic and clinical correlates. Schizophr Bull 1990; 16: 31-56.
100. Mueser KT, Bellack AS, Blanchard JJ. Comorbidity of schizophrenia and substance abuse: Implications for treatment. J Consult Clin Psychol 1992; 60: 845-856.
101. Strakowski SM, Tohen M, Stoll AL, et al. Comorbidity in psychosis at first hospitalization. Am J Psychiatry 1993; 150: 752-757.
102. Larsen TK, Melle I, Auestad B, et al. Substance abuse in first-episode non-affective psychosis. Schizophr Res 2006; 88: 55-62.
103. Green B, Young R, Kavanagh D. Cannabis use and misuse prevalence among people with psychosis. Br J Psychiatry 2005; 187: 306-313.
104. Hambrecht M, Häfner H. Substance abuse and the onset of schizophrenia. Biol Psychiatry 1996; 40: 1155-1163.
105. Bersani G, Orlandi V, Kotzalidis GD, et al. Cannabis and schizophrenia: Impact on onset, course, psychopathology and outcomes. Eur Arch Psychiatry Clin Neurosci 2002; 252: 86-92.
106. Graham HL, Maslin J. Problematic cannabis use amongst those with severe mental health problems in an inner city area of the UK. Addictive Behav 2002; 27: 261-273.
107. Dubertret C, Bidard I, Adès J, Gorwood P. Lifetime positive symptoms in patients with schizophrenia and cannabis abuse are partially explained by co-morbid addiction. Schizophr Res 2006; 86: 284-290.
108. Hides L, Dawe S, Kavanagh DJ, Young RM. Psychotic symptom and cannabis relapse in recent-onset psychosis. Br J Psychiatry 2006; 189: 137-143.
109. Cantwell R, Brewin J, Glazebrook C, et al. Prevalence of substance misuse in first-episode psychosis. Br J Psychiatry 1999; 174: 150-153.
110. Hambrecht M, Hafner, H. Cannabis, vulnerability, and the onset of schizophrenia: An epidemiological perspective. Austr NZ J Psychiatry 2000; 34: 468-75.
111. Addington J, Addington D. Impact of an early psychosis program on substance use. Psychiatr Rehab J 2001; 25: 60-68.
112. Compton MT, Furman AC, Kaslow NJ. Lower negative symptom scores among cannabis-dependent patients with schizophrenia-spectrum disorders: Preliminary evidence from an African American first-episode sample. Schizophr Res 2004; 71: 61-64.
113. Barnes TRE, Mutsatsa SH, Hutton SB, et al. Comorbid substance use and age at onset of schizophrenia. Br J Psychiatry 2006; 188: 237-242.
114. Wade D, Harrigan S, Edwards J, et al. Course of substance misuse and daily tobacco use in first-episode psychosis. Schizophr Res 2006a; 81: 145-150.
115. Boydell J, van Os J, Caspi A, et al. Trends in cannabis use prior to first presentation with schizophrenia, in South-East London between 1965 and 1999. Psycholog Med 2006; 36: 1441-1446.
116. Kavanagh DJ, Waghorn G, Jenner L et al. Demographic and clinical correlates of comorbid substancb use disorders in psychosis: Multivariate analyses from an epidemiological sample. Schizophr Res 2004; 66: 115-124.
117. Pencer A, Addington J, Addington D. Outcome of a first episode of psychosis in adolescence: A 2-year follow-up. Psychiatry Res 2005; 133: 35-43.
118. Wade D, Harrigan S, Edwards J, Burgess PM, Whelan G, McGorry PD. Substance misuse in first-episode psychosis: 15-month prospective follow-up study. Br J Psychiatry 2006; 189: 229-234.
119. Montross LP, Barrio C, Yamada AM, et al. Tri-ethnic variations of co-morbid substance and alcohol use disorders in schizophrenia. Schizophr Res 2005; 19: 297-305.
120. Kirkpatrick B, Amador XF, Flaum, M, et al. The deficit syndrome in the DSM-IV Field Trial: I. alcohol and other drug use. Schizophr Res 1996; 20: 69-77.
121. Kirkpatrick B, Messias EM, Tek C. Substance abuse and the heterogeneity of schizophrenia: a population-based study. Schizophr Res 2003; 62: 293-294.
122. Scheller-Gilkey G, Thomas SM, Woolwine BJ, Miller AH. Increased early life stress and depressive symptoms in patients with comorbid substance abuse and schizophrenia. Schizophr Bull 2002; 28: 223-231.
123. Dervaux A, Laqueille X, Bourdel MC, et al. Cannabis and schizophrenia: demographic and clinical correlates. Encephale 2003; 29: 11-17.
124. Lysaker P, Bell M, Beam-Goulet J, Milstein R. Relationship of positive and negative symptoms to cocaine abuse in schizophrenia. J Nerv Ment Dis 1994; 182: 109-112.
125. Salyers MP, Mueser KT. Social functioning, psychopathology, and medication side effects in relation to substance use and abuse in schizophrenia. Schizophr Res 2001; 48: 109-123.
126. Joyal CC, Hallé P, Lapierre D, Hodgins S. Drug abuse and/or dependence and better neuropsychological performance in patients with schizophrenia. Schizophr Res 2003; 63: 297-299.
127. Maremmani I, Lazzeri A, Pacini M, et al. Diagnostic and symptomatological features in chronic psychotic patients according to cannabis use status. J Psychoactive Drugs 2004; 36: 235-241.
128. Potvin S, Sepehry AA, Stip E. A meta-analysis of negative symptoms in dual diagnosis schizophrenia. Psychol Med 2006; 36: 431-440.
129. Talamo A, Centorrino F, Tondo L, et al. Comorbid substance-use in schizophrenia: Relation to positive and negative symptoms. Schizophr Res 2006; 86: 251-255.
130. Mancini-Marïe A, Potvin S, Fahim C, et al. Neural correlates of the affect regulation model in schizophrenia patients with substance use history: A functional magnetic resonance imaging study. J Clin Psychiatry 2006; 67: 342-350.
131. Pencer A, Addington J. Substance use and cognition in early psychosis. J Psychiatry Neurosci 2003; 28: 48-54.
132. van Mastrigt S, Addington J, Addington D. Substance misuse at presentation to an early psychosis program. Soc Psychiatry Psychiatr Epidemiol 2004; 39: 69-72.
133. Stirling J, Lewis S, Hopkins R, White C. Cannabis use prior to first onset psychosis predicts spared neurocognition at 10-year follow-up. Schizophr Res 2005; 75: 135-137.
134. Grech A, van Os J, Jones PB, Lewis SW, Murray RM. Cannabis use and outcome of recent onset psychosis. Eur Psychiatry 2005; 20: 349-353.
135. Owen RR, Fischer EP, Booth BM, et al. Medication non-compliance and substance abuse among patients with schizophrenia. Psychiatr Serv 1996; 47: 853-858.
136. Swofford CD, Kasckow JW, Scheller-Gilkey G, et al. Substance use: A powerful predictor of relapse in schizophrenia. Schizophr Res 1996; 20: 145-151.
137. Dixon L. Dual diagnosis of substance abuse in schizophrenia: Prevalence and impact on outcomes. Schizophr Res 1999; 35: s93-s100.
138. Gearon JS, Bellack AS, Rachbeisel J, Dixon L. Drug-use behavior and correlates in people with schizophrenia. Addict Behav 2001; 26: 51-61.
139. Green AI. Schizophrenia and comorbid substance use disorder: Effects of antipsychotics. J Clin Psychiatry 2005; 66(Suppl. 6): 21-26.
140. Sorbara F, Liraud F, Assens F, Abalan F, Verdoux H. Substance use and the course of early psychosis: A 2-year follow-up of first-admitted subjects. Eur Psychiatry 2003; 18: 133-136.
141. McCleery A, Addington J, Addington D. Substance misuse and cognitive functioning in early psychosis: a 2 year follow-up. Schizophr Res 2006; 88: 187-191.
142. Pope HG Jr, Yurgelun-Todd D. Residual cognitive effects of long-term cannabis use. In: Castle DJ, Murray R. Marijuana and Madness. Cambridge: Cambridge University Press, 2004, 198-210.
143. Negrete JC, Knapp WP, Douglas D, et al. Cannabis affects the severity of schizophrenic symptoms: Results of a clinical survey. Psychol Med 1986; 16: 515-520.
144. Barry KL, Fleming MF, Greenley JR, et al. Characteristics of persons with severe mental illness and substance abuse in rural areas. Psychiatr Serv 1996; 47: 88-90.
145. Caspari D. Cannabis and schizophrenia: Results of a follow-up study. Eur Arch Psychiatry Clin Neurosci 1999; 249: 45-49.
146. Raphael B, Wooding S, Stevens G, Connor J. Comorbidity: Cannabis and complexity. J Psychiatr Pract 2005; 11: 161-176.
147. Lundqvist T, Jonsson S, Warkentin S. Frontal lobe dysfunction in long-term cannabis users. Neurotoxicol Teratol 2001; 23: 437-443.
148. Block RI, O'Leary DS, Hichwa RD, et al. Effects of frequent marijuana use on memory-related regional cerebral blood flow. Pharmacol Biochem Behav 2002; 72: 237-250.
149. Solowij N, Stephens RS, Roffman RA, et al. Cognitive functioning of long-term heavy cannabis users seeking treatment. JAMA 2002; 287: 1123-1131.
150. Potvin S, Stip E, Roy JY. Toxic psychoses as pharmacological models of schizophrenia. Curr Psychiatry Rev 2005; 1: 23-32.
151. Koethe D, Gerth CW, Neatby MA, et al. Disturbances in visual information processing in early states of psychosis and experimental delta-9-tetrahydrocannabinol altered states of consciousness. Schizophr Res 2006; 88: 142-150.
152. D'Souza DC, Abi-Saab WM, Madonick S, et al. Delta-9-tetrahydro-cannabinol effects in schizophrenia: Implications for cognition, psychosis, and addiction. Biol Psychiatry 2005; 57: 594-608.
153. Cone EJ, Johnson RE, Moore JD, Roache JD. Acute effects of smoking marijuana on hormones, subjective effects and performance in male human subjects. Pharmacol Biochem Behav 1986; 24: 1749-1754.
154. Williams JH, Wellman NA, Rawlins JNP. Cannabis use correlates with schizotypy in healthy people. Addiction 1996; 91: 869-877.
155. Mass R, Bardong C, Kindl K, Dahme B. Relationship between cannabis use, schizotypal traits, and cognitive function in healthy subjects. Psychopathol 2001; 34: 209-214.
156. Nunn JA, Rizza F, Peters ER. The incidence of schizotypy among cannabis and alcohol users. J Nerv Ment Dis 2001; 189: 741-748.
157. Dumas P, Saod M, Bouafia S, et al. Cannabis use correlates with schizotypal personality traits in healthy students. Psychiatry Res 2002; 19: 27-35.
158. Bailey EL, Swallow BL. The relationship between cannabis use and schizotypal symptoms. Eur Psychi 2004; 19: 113-114.
159. Schiffman J, Nakamura B, Earleywine K LaBrie J. Symptoms of schizotypy precede cannabis use. Psychiatry Res 2005; 134: 37-42.
160. Skosnik PD, Krishnan GP, Aydt EE, Kuhlenshmidt HA, O'Donnell BF. Psychophysiological evidence of altered neural synchronization in cannabis use: Relationship to schizotypy. Am J Psychiatry 2006; 163: 1798-1805.
161. Barkus EJ, Stirling J, Hopkins RS, Lewis S. Cannabis-induced psychosis-like experiences are associated with high schizotypy. Psychopathol 2006; 39: 175-178.
162. Schaub M, Boesch L, Stohler R. Association between aggressiveness, schizotypal personality traits and cannabis use in Swiss psychology students. Psychiatry Res 2006; 143: 299-301.
163. Korkeila JA, Svirskis T, Heinimaa M, et al. Substance abuse and related diagnoses in early psychosis. Compr Psychiatry 2005; 46: 447-452.
164. Mrazek PJ, Haggerty RJ, Eds. Reducing Risks for Mental Disorders: Frontiers for Preventive Intervention Research. Washington, DC: National Academies Press, Institute of Medicine, 1994.
165. Verdoux H, Tournier M, Cougnard A. Impact of substance use on the onset and course of early psychosis. Schizophr Res 2005; 79: 69-75.
166. Pariante CM, Cotter D. Do degenerative changes operate across diagnostic boundaries? The case for glucocorticoid involvement in major psychiatric disorders. In: Keshavan M, Kennedy J, Murray R. Neurodevelopment and Schizophrenia. Cambridge: Cambridge University Press, 2004, 111-120.